ctDNA Patterns May Predict Outcomes Achieved With mRNA-4157 Plus Pembrolizumab in High-Risk Melanoma

Jeffrey S. Weber, MD, PhD, highlighted key efficacy findings from the mRNA-4157-P201/KEYNOTE-942 trial, expanded on the potential utility of longitudinal ctDNA dynamics as a kinetic marker for clinical outcomes in melanoma, and underscored the importance of continued research on mRNA vaccines paired with standard PD-1 therapy across cancer types.

Related Keywords

Australia , United States , Jeffreys Weber , , Perlmutter Cancer Center , Department Of Medicine , York University , Melanoma Research Program , Grossman School Of Medicine , New York University , Isaac Perlmutter Professor , Mrna Vaccine , Pembrolizumab , Melanoma , Ctdna , High Risk , Jesmo ,